Actively Recruiting
Evaluating Carbetocin Alone Versus Carbetocin Plus Oxytocin Infusion for Blood Loss Prevention in Elective Cesarean Delivery A Randomized, Double-Blind Controlled Study
Led by Mansoura University · Updated on 2026-10-09
332
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether carbetocin alone is as effective as carbetocin combined with supplemental oxytocin infusion in preventing the need for additional uterotonic agents after elective cesarean delivery. This study addresses the uncertainty about whether adding oxytocin provides extra benefit or may be redundant or counterproductive due to receptor desensitization. The trial is a prospective, randomized, double-blind, placebo-controlled non-inferiority study with a pilot phase, involving women aged 18 to 45 undergoing elective cesarean delivery. Participants are assigned to one of two groups one receives carbetocin 100 micrograms intravenously as a single bolus followed by a placebo saline infusion over 4 hours the other receives the same carbetocin bolus followed by an oxytocin infusion 10 IU in saline over 4 hours. Both treatments are administered immediately after umbilical cord clamping under spinal anesthesia. The trial includes a standardized fluid protocol for all participants. During the study, researchers monitor the need for additional uterotonic agents within 24 hours as the primary outcome. Secondary outcomes include detailed measurements of blood loss using gravimetric and formula-based methods, uterine tone assessed at specific intervals, incidence of postpartum hemorrhage and blood transfusions, hemodynamic profiles, and adverse effects. Monitoring continues for 24 hours post-delivery with frequent vital sign assessments and blood tests. The total study duration covers the immediate perioperative period and 24-hour postoperative follow-up.
CONDITIONS
Brief Title
Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial
Research Team
M
Mohamed A Tolba, MD
O
Omar S Al Misnid, MD9
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here